2019

1. A novel naphthoquinone-coumarin hybrid that inhibits BCR-ABL1-STAT5 oncogenic pathway and reduces survival in imatinib-resistant chronic myelogenous leukemia cells

   Frontiers in Pharmacology, Vol. 9, Núm. JAN